XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.23.1

STOCKHOLDERS’ EQUITY | 12 Months Ended
--- | ---
Dec. 31, 2022
Equity [Abstract] |
STOCKHOLDERS’ EQUITY | 11. STOCKHOLDERS’ EQUITY Stock Issued For Acquisition The Company issued 1,055,000 shares of its common stock upon acquiring certain assets of All Cell during the year ended December 31, 2022. See further discussion in note 3. Business Combination. Committed Equity Facility On September 2, 2022, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement with B. Riley. Pursuant to the Purchase Agreement, the Company has the right, in its sole discretion, to sell to B. Riley up to $30.0 million, or a maximum of 2.0 million shares of the Company’s common stock at 97% of the volume weighted average price (“VWAP”) of the Company’s common stock on the trading day, calculated in accordance with the Purchase Agreement, over a period of 24 months subject to certain limitations and conditions contained in the Purchase Agreement. Sales and timing of any sales are solely at the election of the Company, and the Company is under no obligation to sell any securities to B. Riley under the Purchase Agreement. As consideration for B. Riley’s commitment to purchase shares of the Company’s common stock, the Company issued 10,484 shares of its common stock and will issue an additional 10,484 shares of its common stock or a cash payment of $150,000, at the Company’s sole discretion, sometime after the first VWAP purchase occurs. The Company incurred an aggregate cost of approximately $0.4 million in connection with the Purchase Agreement, including the fair value of the 10,484 shares of common stock issued to B. Riley upon the execution of the agreement, which was recorded to prepaid expenses and other current assets on the Balance Sheet to be offset against future proceeds from the sale of the Company’s common stock under the Purchase Agreement. During the year ended December 31, 2022, the Company issued 1,436 shares under this agreement. The proceeds were fully offset by costs previously deferred. Awards Under Stock Incentive Plans On June 9, 2021, the Company’s stockholders approved the Beam Global 2021 Equity Incentive Plan (the “2021 Plan”) under which 2,000,000 shares of the Company’s common stock are allowed to be issued pursuant to the exercise of stock options or other awards granted under such plan in addition to the 630,000 shares previously allowed under the Beam Global 2011 Stock Incentive Plan. The number of shares reserved for issuance under the 2021 Plan will increase automatically on January 1 of each of 2022 through 2031 by the number of shares equal to 5% of the aggregate number of outstanding shares of the Company’s common stock as of the immediately preceding December 31, or a lesser number as may be determined by our board of directors or compensation committee. As of December 31, 2022, 1.9 million shares remain available to grant under the 2021 Plan. Stock Options Stock options are granted to new and existing employees. New employee option grants generally have a term of ten years and vest ratably over four years. Existing employee option grants generally have a term of ten years and vest immediately upon grant. The fair value of each option is estimated on the date of grant using the Black-Scholes option-pricing model. This model incorporates certain assumptions for inputs including a risk-free market interest rate, expected dividend yield of the underlying common stock, expected option life and expected volatility in the market value of the underlying common stock based on our historical volatility. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility because the Company’s stock options and warrants have characteristics different from those of its traded stock, and because changes in the subjective input assumptions can materially affect the fair value estimate. We used the assumptions in the table below and we assumed there would not be dividends granted for the options granted in fiscal 2022 and 2021:
Assumptions for options granted |  |  |  |  |  |  |  |
|  | 2022 |  |  | 2021 |
Expected volatility |  |  | 94.94% - 97.41% |  |  |  | 93.03% - 99.32% |
Expected term |  |  | 5 - 7 Years |  |  |  | 5 - 7 Years |
Risk-free interest rate |  |  | 1.55% - 3.86% |  |  |  | 1.25% - 1.38% |
Weighted average FV |  |  | $13.02 |  |  |  | $19.55 |
Option activity for the years ended December 31, 2022 and 2021 is as follows:
Schedule of option activity |  |  |  |  |  |  |  |
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life
Outstanding at December 31, 2020 |  |  | 341,808 |  |  | $ | 11.27 |  |  |
Granted |  |  | 43,300 |  |  |  | 24.63 |  |  |
Exercised |  |  | (97,192 | ) |  |  | 13.28 |  |  |
Forfeited |  |  | (24,483 | ) |  |  | 23.84 |  |  |
Outstanding at December 31, 2021 |  |  | 263,433 |  |  |  | 11.56 |  |  |
Granted |  |  | 78,400 |  |  |  | 16.72 |  |  |
Exercised |  |  | (1,750 | ) |  |  | 6.67 |  |  |
Forfeited |  |  | (3,325 | ) |  |  | 36.25 |  |  |
Outstanding at December 31, 2022 |  |  | 336,758 |  |  | $ | 12.54 |  |  | 7.04 Years
Exercisable at December 31, 2022 |  |  | 225,360 |  |  | $ | 8.89 |  |  | 6.30 Years
The Company’s stock option compensation expense was $0.9 million and $0.4 million for the years ended December 31, 2022 and 2021, respectively, and there was $1.1 million of total unrecognized compensation costs related to outstanding stock options at December 31, 2022 which will be recognized over 3.9 years. Total intrinsic value of options exercised was immaterial for the year ended December 31, 2022 and $1.8 million during the year ended December 31, 2021. Total intrinsic value of options outstanding and options exercisable were $2.2 million and $1.9 million, respectively, as of December 31, 2022. Number of stock options vested and unvested as of December 31, 2022 were 251,129 and 85,629, respectively. Restricted Stock Units In November 2022, the Company granted 285,000 restricted stock units (RSUs) to its Chief Executive Officer (CEO), half of which contains performance conditions (PSUs). 50% of the RSUs without performance condition vested upon grant, with 25% vesting on February 1st of 2024 and 2025. The number of shares issuable under the PSUs are determined based on the achievement of performance metrics specific to the Company that is measured at the end of fiscal year 2024. A summary of activity of the RSUs for the year ended December 31, 2022 is as follows:
Schedule of restricted stock units |  |  |  |  |  |  |  |  |
|  | PSU Nonvested Shares |  |  | RSU Nonvested Shares |  |  | Weighted-Average Grant-Date Fair Value |
Nonvested at December 31, 2021 |  |  | – |  |  |  | – |  |  | $ | – |
Granted |  |  | 142,500 |  |  |  | 142,500 |  |  |  | 13.05 |
Vested |  |  | – |  |  |  | (71,250 | ) |  |  | 13.05 |
Nonvested at December 31, 2022 |  |  | 142,500 |  |  |  | 71,250 |  |  | $ | 13.05 |
Stock compensation expense related to restricted stock units was $1.1 million during the year ended December 31, 2022, with $2.6 million in unrecognized stock compensation expense remaining to be recognized over 2.2 years as of December 31, 2022. Fair value of restricted stock units vested during the year ended December 31, 2022 was $0.9 million. Restricted Stock Awards The Company issues restricted stock to the members of its board of directors as compensation for such members’ services. Such grants generally vest ratably over four quarters. The Company also issues restricted stock to its CEO, for which generally 50% of the shares granted vest ratably over four quarters and the remaining 50% vest ratably over twelve quarters. The common stock related to these awards are issued to an escrow account on the date of grant and released to the grantee upon vest. The fair value is determined based on the closing stock price of the Company’s common stock on the date granted and the related expense is recognized ratably over the vesting period. A summary of activity of the restricted stock awards for the years ended December 31, 2022 and 2021 is as follows:
Schedule of restricted stock award activity |  |  |  |  |  |
|  |  |  |  | Weighted- |
|  | Nonvested |  |  | Average Grant- |
|  | Shares |  |  | Date Fair Value |
Nonvested at December 31, 2020 |  |  | 46,563 |  |  | $ | 12.28 |
Granted |  |  | 20,444 |  |  |  | 31.41 |
Vested |  |  | (40,513 | ) |  |  | 18.32 |
Forfeited |  |  | (12,825 | ) |  |  | 14.95 |
Nonvested at December 31, 2021 |  |  | 13,669 |  |  |  | 20.45 |
Granted |  |  | 26,136 |  |  |  | 14.68 |
Vested |  |  | (21,940 | ) |  |  | 18.75 |
Nonvested at December 31, 2022 |  |  | 17,865 |  |  | $ | 14.11 |
Stock compensation expense related to restricted stock awards was $0.4 million and $0.7 million during the years ended December 31, 2022 and 2021, respectively. Fair values of restricted stock vested during the years ended December 31, 2022 and 2021 were $0.4 million and $1.4 million, respectively. As of December 31, 2022, there were unreleased shares of common stock representing $0.3 million of unrecognized restricted stock grant expense which will be recognized over two years. Warrants A summary of activity of warrants outstanding for the years ended December 31, 2022 and 2021 is as follows:
Schedule of warrant activity |  |  |  |  |  |  |
|  |  | Number of Warrants |  |  | Weighted Average Exercise Price |
Outstanding at December 31, 2020 |  |  |  | 965,584 |  |  | $ | 6.33 |
Exercised |  |  |  | (445,926 | ) |  |  | 6.40 |
Outstanding at December 31, 2021 |  |  |  | 519,658 |  |  |  | 6.30 |
Exercised |  |  |  | (79,454 | ) |  |  | 6.30 |
Outstanding at December 31, 2022 |  |  |  | 440,204 |  |  | $ | 6.30 |
Exercisable at December 31, 2022 |  |  |  | 440,204 |  |  | $ | 6.30 |
Exercisable warrants as of December 31, 2022 have a weighted average remaining contractual life of 1.30 years. The intrinsic value of the exercisable shares of the warrants at December 31, 2022 was $4.9 million. During the year ended December 31, 2021, 433,937 warrants to purchase shares of the Company’s registered common stock and 11,989 warrants to purchase shares of the Company’s unregistered common stock were exercised generating $2.9 million. The unregistered securities were issued pursuant to the private placement exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended. All warrants exercised during the year ended December 31, 2022 were for the Company’s common stock.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration